nanocapsules emulsion h nanoparticles t �� microparticles fig indomethacin concentrations attained in the aqueous humor following the topical application, in rabbits, of indomethacinloaded carriers and a control drug solution mean values � sd, n = , p depo provera during pregnancy compared with indocollyre p compared can dogs take diflucan with colloidal suspensions depo provera during pregnancy reprinted from ref , with permission from pharmaceutical press immunosuppressive peptide cyclosporin a interestingly, following topical administration of pecl nanocapsules containing cyclosporin a, we observed corneal levels of the drug which were five times higher than those provided by an oily solution topical formulation of cyclosporin typically used these high levels were not, depo provera during pregnancy however, translated into high drug concentrations in the depo provera during pregnancy aqueous humor a result that was attributed to the important hydrophobicity of this peptide and its tendency to associate with lypophylic components therefore, at present, there is a proofofconcept of the efficacy of polyester nanocapsules for enhancing depo provera during pregnancy the concentration of topically applied drugs in the corneal epithelium whether this enhanced concentration may depo provera during pregnancy or may not lead to a favored accumulation depo provera during pregnancy of the drug in the inner eye depo provera during pregnancy is expected to be largely dependent on the depo provera during pregnancy physicochemical characteristics of the drug polysaccharidebased nanoparticles the polyester polymers described above are hydrophobic polymers depo provera during pregnancy that need to be biodegraded into hydrophilic oligomers in order to be eliminated from the body a very different class of polymers, which has only received attention in the last few years, is the one represented by the hydrophilic polysaccharides hyaluronic acid and chitosan are depo provera during pregnancy two types of polysaccharides which have opened new prospects in the ocular drug delivery area the choice of hyaluronic acid has been justified by its bioadhesive character, but also by depo provera during pregnancy its well known safety profile in fact, depo provera during pregnancy hyaluronic acid is already being used as a substitute for vitreous humor in intraocular surgery, depo provera during pregnancy since it constitutes a basic component of the depo provera during pregnancy vitreous body on the other hand, chitosan is a polycationic biopolymer which exhibits several favorable depo provera during pregnancy biological properties for ocular drug administration these hydrochlorothiazide and laxitive and negative effects properties include mucoadhesiveness biodegradability in the rich lysozyme containing mucus ie ocular mucosa, and also depo provera during pregnancy wound healing and antimicrobial activity despite the number of articles showing the efficacy of hyaluronic depo provera during pregnancy acid solutions for improving the retention of drugs applied topically onto the eye, the only particulate formulation that has been tested in vivo depo provera during pregnancy was composed of microparticles zm rather than nanoparticles these hyaluronate microparticles were shown to increase the residence time of the model drug methylprednisolone at the ocular surface of the rabbit depo provera during pregnancy eye taking into account the reported influence of the size on the interaction of particles with the ocular mucosa, we have recently designed depo provera during pregnancy nanoparticles consisting of hyaluronic acid and chitosan at present, we know that these nanoparticles are depo provera during pregnancy stable upon incubation in simulated lachrymal fluids and in vivo studies are in progress in order to evaluate their mechanism of interaction with the ocular mucosa chitosan has also received significant attention in the ophthalmic field one of the chitosanbased systems that has exhibited an interesting behavior following topical ocular administration, is the one consisting of chitosan nanoparticles these nanoparticles depo provera during pregnancy have been tested on the rabbit model for their ability to enhance the concentration of cyclosporin a at the level of the ocular mucosa as expected, the results showed that the chitosan nanoparticles were able to increase the concentrations of cyclosporin a in the external ocular tissues cornea and conjunctiva significantly for up to hr postinstillation fig despite this enhanced retention of the drug in the external depo provera during pregnancy tissues, the levels attained in the internal ocular structures ie aqueous humor, iris and ciliary depo provera during pregnancy body and in the blood were negligible consequently, depo provera during pregnancy these results suggested the utility of this depo provera during pregnancy new formulation for the treatment of surface eye diseases, ie dry eye or inflammatory diseases these high drug concentrations restricted to the periocular tissues were later explained by a high depo provera during pregnancy corneal and conjunctival surface retention of chitosan nanoparticles depo provera during pregnancy indeed, in a study consisting of evaluating the concentration of fluorescent chitosan, either in the form of nanoparticles or as a solution, depo provera during pregnancy in cornea and conjunctiva, we could conclude that depo provera during pregnancy the affinity of chitosan for the ocular surface is greater when it is in a particulate form this conclusion invites interesting prospects depo provera during pregnancy with regard to the potential of chitosan nanoparticles as drug carriers for topical ocular administration keeping this in mind, we tested the acute depo provera during pregnancy tolerance of chitosan nanoparticles following topical instillation depo provera during pregnancy to rabbits very recently the results gave evidence of an excellent tolerance, without any sign depo provera during pregnancy of irritation or damage of the ocular surface structures cya concentration in the cornea ng cyag cornea ?